MAY 28, 2020 8:30 AM PDT

Trial for Arthritis Drug with Remdesivir to Beat COVID-19

WRITTEN BY: Annie Lennon

Montefiore Health System and Albert Einstein College of Medicine in New York have teamed up to see how well remdesivir, a drug already approved for COVID-19 treatment, works with an anti-inflammatory drug known as baricitinib against the virus. 

Preliminary results from clinical trials with remdesivir have shown that the drug is able to reduce recovery times from COVID-19 from 15 days to 11 days. Of the 1,063 patients involved in that trial, 91 were from either Montefiore or Einstein hospitals. 

Expanding on these results, doctors and researchers between these hospitals are studying whether remdesivir in combination with baricitinib can yield even better results. Baricitinib is so far known for reducing inflammation linked to rheumatoid arthritis. The researchers' goal is to determine whether the drug, when taken with remdesivir, reduces or prevents cytokine storms (excessive inflammation), which can overwhelm a patient's lungs and other organs, eventually leading to death. 

To do so, they are conducting a placebo-controlled, double-blind, randomized trial for the drug combination. Patients selected for the trial should be hospitalized with a confirmed COVID-19 diagnosis and lung complications, including abnormal chest X-rays, pneumonia, and need of a mechanical ventilator to breathe. While all patients will receive remdesivir intravenously for up to 10 days, half of the patients will be given baricitinib by mouth, and the other half an identical placebo, for up to two weeks. 

"What concerns us is that in some people the immune response to coronavirus can be more deadly than the infection itself, and there is no known treatment for this yet," says Barry Zingman, one of the study's authors also involved in the original remdesivir study. 

"Including baricitinib in our trial may reduce COVID-19-related inflammation and combining baricitinib with remdesivir may yield an even more effective treatment option for people most severely affected by this illness." 


Sources: Science Daily, News Medical

About the Author
  • Science writer with a keen interest in behavioral biology, consciousness medicine and technology. Her current focus is how the interplay of these fields can create meaningful interactions, products and environments.
You May Also Like
MAR 16, 2021
Drug Discovery & Development
Machine Learning Speeds Up Drug Discovery
MAR 16, 2021
Machine Learning Speeds Up Drug Discovery
How do drugs work? Well, they work when they stick to their target protein. Of course, there is much more complicated pr ...
APR 02, 2021
Technology
Protein Modeling of SARS-CoV-2 Provides Targets for Vaccine Development
APR 02, 2021
Protein Modeling of SARS-CoV-2 Provides Targets for Vaccine Development
Recent protein modeling of the SARS-CoV-2 spike protein reveals novel areas for vaccine development. The novel SARS-CoV- ...
APR 10, 2021
Drug Discovery & Development
How New ADHD Drug for Children Differs from Adderall
APR 10, 2021
How New ADHD Drug for Children Differs from Adderall
Over 1 in 10 children in the US aged between 5 and 17 have been diagnosed with attention deficit hyperactivity ...
MAY 06, 2021
Drug Discovery & Development
Are Hallucinations Necessary for Psychedelics to Treat Depression?
MAY 06, 2021
Are Hallucinations Necessary for Psychedelics to Treat Depression?
Many who work with psychedelics say that hallucinations, or psychedelic experiences, are an integral part of psychedelic ...
MAY 12, 2021
Technology
Belkin Laser Completes Enrollment for Trial Studying New Glaucoma Laser Treatment
MAY 12, 2021
Belkin Laser Completes Enrollment for Trial Studying New Glaucoma Laser Treatment
Belkin Laser, a small Israel-based biotechnology company, has announced that it has completed enrollment for its pivotal ...
JUN 02, 2021
Cannabis Sciences
Can CBD Help Manage Symptoms of Diabetes?
JUN 02, 2021
Can CBD Help Manage Symptoms of Diabetes?
As cannabidiol (CBD) products become increasingly mainstream, more people are using them to manage symptoms for chronic ...
Loading Comments...